- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04860700
The Efficacy and Safety of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
A Phase 2 Study of Anlotinib in Patients With Metastatic Pheochromocytoma or Paraganglioma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
To determine the anti-tumor activity of anlotinib hydrochloride (Objective Response rate,ORR) in patients with metastatic pheochromocytomas or paragangliomas.
SECONDARY OBJECTIVES:
I. To assess safety profile of anlotinib. II. To assess progression-free survival time. III. To assess disease control rate.
OUTLINE:
Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Patients undergo urine and blood sample collection, imaging examinations at baseline and periodically during study.
After completion of study therapy, patients are followed up every 3-6 months.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: anli tong
- Phone Number: 0086-13911413589
- Email: tonganli@hotmail.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Peking Union Medical College Hospital
-
Contact:
- anli tong
- Phone Number: 0086-13911413589
- Email: tonganli@hotmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provide written informed consent.
- Willing to return to enrolling institution for follow-up.
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
- Life expectancy > 3 months.
- Patients diagnosis with metastatic pheochromocytoma or paraganglioma that is unresectable.
- Laboratory requirements:
1)Absolute granulocyte count (AGC) greater than 1.5 x 109/L; 2)Platelet count greater than 80 x 109/L; 3) Hemoglobin greater than 90g/L; 4) Serum bilirubin less than 1.5 x upper limit of normal (ULN); 5)Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 2.5 x ULN; 6) Serum creatinine less than 1.5 x ULN or creatinine clearance (CCr)≥60ml/min; 7.Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%).
Exclusion Criteria:
- Any of the following:Pregnant women,Nursing women,Men or women of childbearing potential who are unwilling to employ adequate contraception.
- Patients who have previously used other anti-vascular targeted drugs, such as sunitinib, bevacizumab, endurance, etc.
- Chemotherapy/systemic therapy, radiotherapy, immunotherapy or surgery within 4 weeks prior to kinase inhibitor therapy.
- Patients with another primary malignancy within 5 years prior to starting study drug, with the exception of adequately treated in-situ carcinoma of the uterine cervix, or skin cancer (such as basal cell carcinoma, squamous cell carcinoma, or non-melanomatous skin cancer).
- Those who have multiple factors that affect oral medications (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.).
- Patients with known untreated brain metastases are excluded. Patients having a history of brain metastasis that have been previously irradiated or resected greater than 2 months prior to enrollment and are clinically and radiographically stable will be considered for enrollment. Patients with brain metastases with symptoms or symptom control for less than 2 months.
- Active or uncontrolled intercurrent illness including, but not limited to 1)Patients with unsatisfactory blood pressure control (systolic blood pressure ≥150 mmHg, diastolic blood pressure ≥100 mmHg); 2) Patients with uncontrolled myocardial ischemia or myocardial infarction, arrhythmia (including QTC≥480ms), and uncontrolled congestive heart failure,grade ≥2(New York Heart Association ); 3) ongoing or active infection; 4) Liver cirrhosis, decompensated liver disease, active hepatitis or chronic hepatitis require antiviral treatment; 5) Renal failure requires hemodialysis or peritoneal dialysis; 6) Have a history of immunodeficiency, including HIV or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 7) Diabetes is poorly controlled (fasting blood glucose (FBG)> 10mmol/L); 8) Urine routines suggest that urine protein is ≥++, and the 24-hour urine protein content is confirmed to be greater than 1.0 g; 9) Patients who have seizures and need treatment;
- Any of the following conditions =< 6 months prior to registration: Cerebrovascular accident (CVA) or transient ischemic attack (TIA); Serious or unstable cardiac arrhythmia; Pulmonary embolism, untreated deep venous thrombosis (DVT).
- Received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before enrollment.
- Those who have a history of psychotropic drug abuse and cannot be quit or have mental disorders.
- Imaging shows that the tumor has invaded important blood vessels or the investigator judges that the tumor is very likely to invade important blood vessels and cause fatal bleeding during the follow-up study.
- Regardless of the severity, patients with any signs of bleeding or medical history; within 4 weeks before enrollment, patients with any bleeding or bleeding event ≥ CTCAE grade 3, unhealed wounds, ulcers or fractures.
- Participated in other clinical trials within 4 weeks.
- Patients are using drugs that interact with Anlotinib.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: anlotinib hydrochloride
Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response rate RECIST Using Version 1.1
Time Frame: minimum of 4 cycles
|
Defined for all patients whose tumor met the criteria of Complete Response (CR)and Partial Response (PR)
|
minimum of 4 cycles
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Control Rate
Time Frame: minimum of 4 cycles
|
Defined for all patients whose tumor met the criteria of CR or PR or stable disease(SD)
|
minimum of 4 cycles
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival Time
Time Frame: minimum of 4 cycles
|
PFS is defined as the time from the first day of treatment to the first documented disease progression per RECIST 1.1 criteria and the Kaplan-Meier curve.
Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria.
|
minimum of 4 cycles
|
Incidence of adverse events assessed by Common Terminology Criteria for Adverse safety profile of anlotinib
Time Frame: minimum of 4 cycles
|
Incidence of adverse events assessed by Common Terminology Criteria for Adverse Events version 4.0
|
minimum of 4 cycles
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anli Tong, Peking Union Medical College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCHMPPGL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Paraganglioma, Extra-Adrenal
-
National Cancer Institute (NCI)TerminatedParaganglioma | Metastatic Adrenal Gland Pheochromocytoma | Recurrent Adrenal Gland Pheochromocytoma | Extra-Adrenal ParagangliomaUnited States, Singapore, Hong Kong
-
Seoul National University HospitalCompletedPheochromocytoma | Extra-adrenal Paraganglioma | Non-functioning CarcinoidKorea, Republic of
-
National Cancer Institute (NCI)RecruitingMetastatic Adrenal Gland Pheochromocytoma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Advanced Adrenal Gland Pheochromocytoma | Advanced Paraganglioma | Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8 | Stage...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMetastatic Adrenal Gland Pheochromocytoma | Locally Advanced Paraganglioma | Metastatic Paraganglioma | Unresectable Adrenal Gland Pheochromocytoma | Unresectable Paraganglioma | Regional Adrenal Gland PheochromocytomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMetastatic Adrenal Gland Pheochromocytoma | Malignant Adrenal Gland Pheochromocytoma | Malignant ParagangliomaUnited States
-
University of AarhusCompletedPheochromocytoma | Adrenal IncidentalomaDenmark
-
Central Hospital, Nancy, FranceRecruitingPheochromocytoma | Non-Secretory Adrenal AdenomaFrance
-
Zagazig UniversityCompleted
-
Seoul National University HospitalSamsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaboratorsRecruitingDevelopment of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World DataPrimary Aldosteronism | Cushing Syndrome | Pheochromocytoma | Adrenal Cortical Carcinoma | Adrenal TumorKorea, Republic of
-
EnteromeActive, not recruitingPheochromocytoma | Paraganglioma | Adrenocortical CarcinomaUnited States, France, Spain, Denmark, Sweden, Germany, Italy, Netherlands
Clinical Trials on anlotinib hydrochloride
-
First People's Hospital of HangzhouChia Tai Tianqing Pharmaceutical Group Co., Ltd.RecruitingRecurrent High-grade GliomaChina
-
Peng YuanCompletedBreast Neoplasm | Antineoplastic Agents | AnlotinibChina
-
Peking Union Medical College HospitalRecruitingPheochromocytoma | ParagangliomaChina
-
Sun Yat-sen UniversityChia Tai Tianqing Pharmaceutical Group Co., Ltd.Recruiting
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Small Cell Lung Cancer | Lung NeoplasmChina
-
First Hospital of Shijiazhuang CityUnknownCarcinoma | Non-small Cell Lung Cancer | Lung NeoplasmChina
-
Peking Union Medical College HospitalRecruiting
-
Sun Yat-sen UniversityRecruitingSarcoma,Soft TissueChina
-
Peking University Third HospitalNot yet recruitingNon-Small Cell Lung Cancer
-
Cancer Institute and Hospital, Chinese Academy...RecruitingAnlotinib | Sarcoma,Soft Tissue | Trunk | Extremity | Intensity-modulated Radiotherapy | Major Wound ComplicationsChina